Skip to content

Remifentanil patient gecontroleerde pijnstilling versus epidurale pijnstilling tijdens de bevalling.

Remifentanil patient controlled analgesia versus epidural analgesia during labour. A randomized multicenter trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON28699
Enrollment
1136
Registered
2010-10-04
Start date
2011-05-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

remifentanil, PCA, epidural, analgesia, labour

Interventions

Women will be randomized before actual labour starts. They will know which method of pain relief they are assigned. In the need for pain relief arrises they will be treated with remifentanil PCA or ep

Sponsors

LUMC
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age >18 years; 2. Labour between 32 and 42 weeks; 3. ASA physical status 1 or 2.

Exclusion criteria

Exclusion criteria: 1. Prior administration of opioid or regional analgesia; 2. Drug allergy, hypersensitivity tot opiod or local analgesia substances; 3. Initial maternal SpO2 38 degrees C; 5. Contra-indication for epidural analgesia.

Design outcomes

Primary

MeasureTime frame
This study will assess in women with a request for pain relief during labour the cost-effectiveness of RPCA as first choice treatment compared to EA. The economic analysis will be performed from a short-term healthcare perspective. Anticipating on equality in pain relief scores the economic analysis will be a cost minimization analysis. For both strategies the cost of perinatal care for mother and child, starting at the onset of labor and ending ten days after delivery, will be registered and compared (without discounting). The costs consist of costs of delivery/childbirth (course and mode of delivery), postnatal maternal care (hospitalization, outpatient visits), neonatal care (admission to NICU/neonatology ward, outpatient visits) and primary care (midwife, general practitioner, maternity care). Volumes of hospital care are measured prospectively alongside the clinical study in all participating centers as part of the case record form. Health resource use outside the hospital will be recorded by questionnaires filled out by the patients. Costs of delivery/childbirth are estimated by a detailed cost price analysis in which units of resource use (time of hospital staff, materials, equipment) are valued using cost per unit estimates comprising "true economic" costs, i.e. including shares of fixed costs and hospital overheads. Costs per units are estimated for both a teaching and a non-teaching hospital. A secondary analysis based on reimbursement fees will be performed. Other resource use (hospital days, outpatient visits and primary care) will be valued using standard prices.

Secondary

MeasureTime frame
We will also look at the following outcomes: 1. Pain relief scores; 2. Patient satisfaction; 3. Pain scores; 4. Maternal and neonatal side effects. Pain scores and pain relief scores will be assessed using a visual analogue scale (VAS). For pain scores women will be asked to mark the level of pain experienced during contractions every hour, starting with a baseline VAS score before the institution of analgesia. Pain relief scores will be asked every hour and after delivery an overall satisfaction score (0-10) will be asked. Patient satisfaction will also be assesed by HADS and WDQ (Wijma Delivery Expectancy/Experience Questionnaire). Baseline non-invasive measurements will be made at regular intervals, including maternal blood pressure, heart rate, respiratory rate and pulse oximetry. Fetal heart rate and uterine activity will be measured continuously. Observations for known side effects will be made; respiratory depression, nausea/vomiting and itching. Side-effects will be managed by established protocols. At delivery neonatal outcome including Apgar scores and cord blood gas analysis and the Neurologic and Adaptive Capacity Score (NACS) and MAIN score will be recorded.

Contacts

Public ContactL.M. Freeman

Postbus 9600

l.m.freeman@lumc.nl+31 (0)6 45454887

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)